ProPhase Labs (NASDAQ:PRPH) Share Price Passes Below 200 Day Moving Average – Time to Sell?

Shares of ProPhase Labs, Inc. (NASDAQ:PRPH) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.61 and traded as low as $0.0750. ProPhase Labs shares last traded at $0.0801, with a volume of 45,564 shares.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded ProPhase Labs to a “hold” rating in a report on Saturday, December 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

ProPhase Labs Trading Down 7.7%

The company has a current ratio of 0.14, a quick ratio of 0.14 and a debt-to-equity ratio of 0.14. The business’s 50-day simple moving average is $0.13 and its two-hundred day simple moving average is $1.61. The company has a market capitalization of $482,362.20, a PE ratio of -0.02 and a beta of -0.33.

Hedge Funds Weigh In On ProPhase Labs

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PRPH. XTX Topco Ltd purchased a new position in ProPhase Labs in the 2nd quarter valued at about $40,000. Apollon Wealth Management LLC purchased a new position in ProPhase Labs in the 3rd quarter valued at about $84,000. Accretive Wealth Partners LLC purchased a new position in ProPhase Labs in the 3rd quarter valued at about $114,000. Finally, Susquehanna International Group LLP boosted its position in ProPhase Labs by 290.1% in the 3rd quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock valued at $182,000 after buying an additional 295,899 shares during the last quarter. 9.45% of the stock is owned by hedge funds and other institutional investors.

ProPhase Labs Company Profile

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.